Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis

Archives of Internal Medicine

Volumn 160, Issue 19, 2000, Pages 2998-3003

  Watson, D J ^a   Harper, S E ^a   Zhao, P L ^a   Quan, H ^a   Bolognese, J A ^a   Simon, T J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NABUMETONE; ROFECOXIB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0034706411     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.19.2998     Document Type: Article

References (31)

1. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: Effects of interleukin-1β, phorbol ester, and corticosteroids
2. Human cyclooxygenase-2 cDNA
3. Identification of a pharmacologically distinct prostaglandin H synthetase in cultured epithelial cells
4. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthetase in rat preovulatory follicles: Induction in vivo and in vitro
5. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease
6. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal antiinflammatory drugs
7. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system
8. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
9. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use
10. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
11. Prediction of organ system toxicity with antirheumatic drug therapy
12. Dyspepsia in patients with rheumatoid arthritis
13. Gastroscopic evaluation of anti-inflammatory agents
14. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
15. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
16. Demonstration of specific COX-2 inhibition by MK-966 (VIOXX) in humans with supratherapeutic doses
17. Effects of a novel cyclooxygenase (COX)-2 inhibitor on gastric mucosal prostaglandin (PG) synthesis in healthy humans
18. 2) synthesis in humans
19. COX-2 specific inhibition with MK-096625 or 50 mg Q.D. does not increase intestinal permeability: A controlled study with placebo (PBO) and indomethacin 50 mg T.I.D. (INDO)
20. COX-2 specific inhibition with MK-096625 or 50 mg Q.D. over 4 weeks does not increase fecal blood loss: A controlled study with placebo and ibuprofen 800 mg T.I.D
21. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg Q.D.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg Q.I.D. or ibuprofen (IBU) 890 mg T.I.D
22. Effect of the COX-2 specific inhibitor (C-2SI) rofecoxib on ulcer formation: A double blind comparison with ibuprofen and placebo
23. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
24. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
25. MK-0966, a specific COX-2 inhibitor has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial
26. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial
27. MK-966, a highly selective COX-2 inhibitor was effective in the treatment of osteoarthritis of the knee and hip in a 6-week placebo controlled study
28. Rofecoxib, a COX-2 specific inhibitor, had clinical efficacy and overall safety in treating osteoarthritis patients aged 80 years and older
29. Review of clinical trials and benefit/risk ratio of meloxicam